findmyKOL
Clinical trialNCT05202327CompletedPhase 2Interventional

PDC-1421 Treatment in Adult Patients With ADHD

SponsorBioLite, Inc.Enrollment99Attention-Deficit Hyperactivity Disorder (ADHD)
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Taiwan
  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan

  • Cheng Hsin General Hospital

    Taipei, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Linkou Chang Gung Memorial Hospital

    Taoyuan, Taiwan

United States
  • University of California, San Francisco

    San Francisco, California, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 Apr 2022
Primary completion
6 Dec 2023
Completion
8 Apr 2024
Last update posted
6 May 2026
Registered enrollment
99
Registry id
NCT05202327

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.